The topic of ‘changing the name of aHUS’ crops up regularly, so since people keep asking here are details which might help to greater clarity and understanding to this topic.…
It’s amazing how quickly medicine advances. For patients with some diagnoses, it seems like aspects such as new treatments or ‘standard of care’ guidelines can’t move forward quickly enough. It’s…
Scientific advancements in the last decade have yielded promising avenues on multiple fronts, including those related to atypical HUS and other thrombotic microangiopathies. However we’ve now reached a point where…
Article No. 451 4 August 2021 Following on swiftly from Article No. 450 about the current babble of names and need to rename aHUS, aHUS alliance Global Action has been…
CAPS or Catastrophic Antiphospholipid Syndrome is an autoimmune and kidney disease which shares the same experience of thrombotic microangiopathy with aHUS/ cTMA. It is a rare life threatening diseases which…
aHUS Global Advocate Newsletter: May 2026 Edition Where can you get aHUS news that’s independent, objective, and focused on what’s important to the atypical HUS community? Here! We’re pleased to…
The name atypical hemolytic uremic syndrome is being replaced. Complement mediated thrombotic microangiopathy is becoming a popular choice. The first term is explicitly associated with kidney disease, the second term…
What’s new in aHUS research? Quite a bit, if you consider that over four dozen publications have just been added to our aHUS-specific ‘Virtual Library’. There’s a reason we’re so…